Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of GTL 001 against HPV 16/18 infections

Next Previous
Trial Profile

A phase III trial of GTL 001 against HPV 16/18 infections

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GTL 001 (Primary)
  • Indications Human papillomavirus infections
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 30 Sep 2016 According to a GENTICEL media release, a previous phase II study (Profile 700237810) did not show statistical difference in viral clearance between the treated group and the placebo group in the total population based on which the company has decided not make any further investment towards a phase III program of GTL-001.
  • 30 Sep 2016 Status changed from planning to withdrawn prior to enrolment, according to a GENTICEL media release.
  • 28 Jan 2016 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top